CRL · News · 20260805N
Acquisition / Partnership / Divestiture
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. · 2026-08-05 · Importance 37 · Surprise 42 · In source text
Charles River continued refining its portfolio through strategic divestitures, which contributed to Q2 GAAP divestiture losses. Management cited a Cambodian non-human-primate supplier acquisition as part of its strategic M&A activity. The acquisition supports non-human-primate sourcing and contributed to lower sourcing costs in Discovery and Safety Assessment. Executives said the company remains comfortable with its post-divestiture portfolio and retains an appetite for additional M&A.
Key facts
- Company referenced a planned or completed strategic acquisition of a 'Cambodian NHP supplier.' source
- Company cited divestiture losses as a primary reason for the Q2 2026 GAAP net loss. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Company referenced a planned or completed strategic acquisition of a 'Cambodian NHP supplier.' |
| assets | positive | probable | — | Company referenced a planned or completed strategic acquisition of a 'Cambodian NHP supplier.' |